

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

INSIDE INFORMATION

PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC XNW**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC XNW has published its 2022 Annual Report (“**Annual Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC XNW prepared in accordance with the PRC Accounting Standard for Business Enterprises for the year ended 31 December 2022.

The information in the Appendices is an extract of the Annual Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 17 March 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

APPENDIX I
PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS

Unit: RMB (Yuan)

	2022	2021		Increase/ decrease compared with last year	2020	
		Before adjustment	After adjustment		After adjustment	Before adjustment
Revenue	2,626,488,832.63	1,431,987,664.46	1,849,677,007.18	42.00%	1,317,414,122.08	1,629,384,050.96
Net profit attributable to listed company's shareholders	726,277,891.97	317,071,430.99	393,228,489.93	84.70%	299,835,756.44	332,168,769.41
Net profit attributable to listed company's shareholders excluding non-recurring gain/loss	657,608,747.31	298,498,249.98	298,498,249.98	120.31%	263,188,500.07	263,188,500.07
Net cash flows arising from operating activities	640,717,518.79	170,592,336.20	292,085,994.15	119.36%	349,071,664.26	356,945,696.32
Basic earnings per share (Yuan/share)	1.1734	0.5807	0.6353	84.70%	0.5491	0.5367
Diluted earnings per share (Yuan/share)	1.1734	0.5807	0.6353	84.70%	0.5491	0.5367
Weighted average return on net assets	20.11%	11.29%	13.41%	6.70%	11.82%	12.83%
	End of 2022	End of 2021		Increase/ decrease compared with the end of last year	End of 2020	
		Before adjustment	After adjustment		After adjustment	Before adjustment
Total assets	4,584,035,512.38	3,225,776,209.68	3,741,208,950.36	22.53%	2,954,902,756.59	3,315,347,935.58
Net assets attributable to listed company's shareholders	3,935,600,634.14	2,952,078,874.74	3,289,370,322.06	19.65%	2,678,111,938.23	2,763,471,118.28

APPENDIX II
NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

Unit: RMB (Yuan)

Items	Amounts in 2022	Amounts in 2021	Amounts in 2020	Description
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	-4,562,657.58	-7,384,221.62	-430,725.37	
Government grants recognised in profit or loss of current period (excluding those closely related to the company's normal operating business and continuously granted according to certain quota of amount or volume under national policies)	4,865,650.37	18,300,150.56	23,098,080.33	
Gain/loss from entrusted investments or assets management	6,517,950.19	10,618,573.52	22,978,112.40	
Net current profit or loss of subsidiaries from the beginning of the period to the consolidation date arising from business combination under common control	63,201,256.20	76,157,058.94	32,333,012.97	
Other non-operating income and expenses other than the above items	59,880.88	-898,539.74	-435,965.16	
Other items of profit or loss falling within the definition of non-recurring gains and losses	-	3,380,349.16	-	
Less: Impact of income tax	1,413,003.18	5,421,843.96	8,567,097.89	
Impact of minority interests (after tax)	-67.78	21,286.91	-4,852.06	
Total	68,669,144.66	94,730,239.95	68,980,269.34	-

APPENDIX III SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: RMB (Yuan)

	End of 2022		Beginning of 2022		Percentage increase/decrease	Description on significant changes
	Amount	Percentage of total asset	Amount	Percentage of total asset		
Cash and bank balances	2,195,684,427.95	47.90%	1,244,407,449.36	33.26%	14.64%	Mainly due to the increase in cash and bank balances received by the company for goods sold and redemption upon maturity of the company's cash management.
Trade receivables	481,379,233.73	10.50%	326,807,311.55	8.74%	1.76%	No significant changes
Inventories	238,125,791.53	5.19%	262,003,480.59	7.00%	-1.81%	No significant changes
Long-term equity investments	253,488,895.12	5.53%	243,185,931.33	6.50%	-0.97%	No significant changes
Fixed assets	984,018,362.29	21.47%	630,627,580.72	16.86%	4.61%	Mainly due to the transfer of "Acarbose Green Factory Technological Upgrading and Transformation Project" to fixed assets.
Construction in progress	70,735,076.79	1.54%	294,970,794.80	7.88%	-6.34%	Mainly due to the transfer of certain construction in progress of the company to fixed assets.
Right-of-use assets			823,153.61	0.02%	-0.02%	No significant changes
Contract liabilities	68,259,661.19	1.49%	30,366,227.10	0.81%	0.68%	No significant changes
Long-term borrowings	19,800,000.00	0.43%	0.00	0.00%	0.43%	Mainly due to the increase in bank borrowing of CSPC Shengxue.